Announcement on Obtaining the "Drug Clinical Trial Approval Notice" for Innovative Drug HSK46256 Tablets

Haisco Pharmaceutical Group Co., Ltd.·June 11, 2026·2 pages

✨ AI Summary

This announcement details that Hansoh Pharmaceutical Group has received approval from the NMPA for the clinical trial of its innovative drug HSK46256 tablets. The drug, developed in-house, targets late-stage solid tumors, particularly those associated with BRCA mutations. The company has been granted approval to commence clinical trials for this promising small molecule drug.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002653

Securities Abbreviation: Hansoh Pharma

Announcement Number: 2026-061

Hansoh Pharmaceutical Group Co., Ltd.

Announcement on Obtaining the "Drug Clinical Trial Approval Notice" for Innovative Drug HSK46256 Tablets

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or material omissions.

Hansoh Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, and the relevant situation is hereby announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.